If you or someone you care for has been diagnosed with treatment-resistant, severe schizophrenia, you should know about CLOZARIL and how it may help in this type of mental illness.

Results from the International Suicide Prevention Trial (InterSePT™) have demonstrated that CLOZARIL can reduce the risk of suicidal behavior in people with schizophrenia or schizoaffective disorder. People with schizoaffective disorder have symptoms of both schizophrenia and mood disorders, such as mental or physical mania (overactivity). CLOZARIL can reduce the risk of repeated suicidal behavior in schizophrenia or in people with schizoaffective disorder.

CLOZARIL: Atypical Antipsychotic

CLOZARIL is an atypical antipsychotic (a family of drugs used to treat people suffering from schizophrenia). CLOZARIL requires that people – and their health care prescribers – make a commitment to therapy. A blood disorder called agranulocytosis has been associated with CLOZARIL. In the disorder, white blood cells are not made – or not enough of them are made. This reduces the body’s resistance to infection. People who take CLOZARIL must have their WBC and ANCs monitored to prevent or greatly reduce the risk of developing agranulocytosis.